Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

94.26 +3.04 (+3.33%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 29, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	928,747
Open	91.55
Bid (Size)	94.20 (700)
Ask (Size)	94.26 (400)
Prev. Close	91.22
Today's Range	91.27 - 94.37
52wk Range	79.52 - 124.00
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

2 Biotech Stocks Worth Buying Before Their Potential Buyouts ↗

June 27, 2026

It has been a banner year for biotech buyouts, and these are two of the prime targets.

Via The Motley Fool

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

May 30, 2026

From BioNTech SE

Via GlobeNewswire

Performance

YTD	-2.5%	-2.5%
1 Month	-1.8%	-1.8%
3 Month	+10.6%	+10.6%
6 Month	-1.0%	-1.0%
1 Year	-11.5%	-11.5%

More News

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

May 22, 2026

From BioNTech SE

Via GlobeNewswire

BioNTech Q1 2026 Revenue Miss Overshadows Pipeline Progress as NASDAQ:BNTX Slides ↗

May 05, 2026

Via Chartmill

BioNTech SE (NASDAQ:BNTX) Stock Plummets 17% on Q4 Loss and Co-Founders' Planned Exit ↗

March 10, 2026

Via Chartmill

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

May 15, 2026

From BioNTech SE

Via GlobeNewswire

BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM ↗

May 15, 2026

Via MarketBeat

3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗

May 13, 2026

Via The Motley Fool

Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors. ↗

May 11, 2026

Via The Motley Fool

BioNTech Announces New ADS Repurchase Program

May 07, 2026

From BioNTech SE

Via GlobeNewswire

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

May 05, 2026

From BioNTech SE

Via GlobeNewswire

BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026

April 21, 2026

From BioNTech SE

Via GlobeNewswire

2 Healthcare Stocks to Buy and 1 to Approach With Caution ↗

April 15, 2026

Via The Motley Fool

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

April 11, 2026

From BioNTech SE

Via GlobeNewswire

Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability

March 31, 2026

Via Finterra

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

March 24, 2026

From BioNTech SE

Via GlobeNewswire

The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery

March 16, 2026

Via MarketMinute

Why BioNTech Stock Is Getting Crushed Today ↗

March 10, 2026

Via The Motley Fool

Gapping stocks in Tuesday's session ↗

March 10, 2026

Via Chartmill

BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier

March 10, 2026

Via MarketMinute

Stay updated with the stocks that are on the move in today's pre-market session. ↗

March 10, 2026

Via Chartmill

Why Did BNTX Stock Tumble 17% Pre-Market Today? ↗

March 10, 2026

Via Stocktwits

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

March 10, 2026

From BioNTech SE

Via GlobeNewswire

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

March 10, 2026

From BioNTech SE

Via GlobeNewswire

The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology

March 06, 2026

Via Finterra

Frequently Asked Questions

Is BioNTech SE - American Depositary Shares publicly traded?

Yes, BioNTech SE - American Depositary Shares is publicly traded.

What exchange does BioNTech SE - American Depositary Shares trade on?

BioNTech SE - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for BioNTech SE - American Depositary Shares?

The ticker symbol for BioNTech SE - American Depositary Shares is BNTX on the Nasdaq Stock Market

What is the current price of BioNTech SE - American Depositary Shares?

The current price of BioNTech SE - American Depositary Shares is 94.26

When was BioNTech SE - American Depositary Shares last traded?

The last trade of BioNTech SE - American Depositary Shares was at 06/29/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.